Logo image of DICE

DICE Therapeutics Inc (DICE) Stock Fundamental Analysis

NASDAQ:DICE - Nasdaq - US23345J1043 - Common Stock - Currency: USD

47.55  +0.03 (+0.06%)

After market: 47.59 +0.04 (+0.08%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to DICE. DICE was compared to 195 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for DICE as it has an excellent financial health rating, but there are worries on the profitability. DICE does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year DICE has reported negative net income.
DICE had a negative operating cash flow in the past year.
DICE Yearly Net Income VS EBIT VS OCF VS FCFDICE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 -20M -40M -60M -80M

1.2 Ratios

The profitability ratios for DICE are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
DICE Yearly ROA, ROE, ROICDICE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 -10 -20 -30 -40

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for DICE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DICE Yearly Profit, Operating, Gross MarginsDICE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 -1K -2K -3K -4K

More info and screens

8

2. Health

2.1 Basic Checks

DICE does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, DICE has more shares outstanding
There is no outstanding debt for DICE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
DICE Yearly Shares OutstandingDICE Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 10M 20M 30M 40M
DICE Yearly Total Debt VS Total AssetsDICE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 100M 200M 300M 400M 500M

2.2 Solvency

An Altman-Z score of 47.54 indicates that DICE is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 47.54, DICE belongs to the top of the industry, outperforming 98.10% of the companies in the same industry.
DICE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 47.54
ROIC/WACCN/A
WACC8.94%
DICE Yearly LT Debt VS Equity VS FCFDICE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 0 200M 400M

2.3 Liquidity

A Current Ratio of 32.44 indicates that DICE has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 32.44, DICE belongs to the top of the industry, outperforming 97.14% of the companies in the same industry.
DICE has a Quick Ratio of 32.44. This indicates that DICE is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of DICE (32.44) is better than 97.62% of its industry peers.
Industry RankSector Rank
Current Ratio 32.44
Quick Ratio 32.44
DICE Yearly Current Assets VS Current LiabilitesDICE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 100M 200M 300M 400M 500M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for DICE have decreased strongly by -20.98% in the last year.
DICE shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)-20.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, DICE will show a very negative growth in Earnings Per Share. The EPS will decrease by -14.28% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-22.45%
EPS Next 2Y-26.68%
EPS Next 3Y-23.74%
EPS Next 5Y-14.28%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
DICE Yearly Revenue VS EstimatesDICE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2025 2026 2027 2028 2029 2030 200M 400M 600M
DICE Yearly EPS VS EstimatesDICE Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4 -4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

DICE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year DICE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DICE Price Earnings VS Forward Price EarningsDICE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DICE Per share dataDICE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

A cheap valuation may be justified as DICE's earnings are expected to decrease with -23.74% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-26.68%
EPS Next 3Y-23.74%

More info and screens

0

5. Dividend

5.1 Amount

DICE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DICE Therapeutics Inc

NASDAQ:DICE (8/8/2023, 9:37:47 PM)

After market: 47.59 +0.04 (+0.08%)

47.55

+0.03 (+0.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-10 2023-08-10/amc
Earnings (Next)N/A N/A
Inst Owners0.04%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap2.27B
Analysts52.86
Price Target50.36 (5.91%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.31%
Min EPS beat(2)-2.95%
Max EPS beat(2)9.57%
EPS beat(4)2
Avg EPS beat(4)3.48%
Min EPS beat(4)-2.95%
Max EPS beat(4)9.75%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.31%
PT rev (3m)-20.2%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.58%
EPS NY rev (1m)2.5%
EPS NY rev (3m)2.5%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.16
P/tB 4.16
EV/EBITDA N/A
EPS(TTM)-2.18
EYN/A
EPS(NY)-3.43
Fwd EYN/A
FCF(TTM)-1.56
FCFYN/A
OCF(TTM)-1.52
OCFYN/A
SpS0
BVpS11.44
TBVpS11.44
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 223.75%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 32.44
Quick Ratio 32.44
Altman-Z 47.54
F-Score3
WACC8.94%
ROIC/WACCN/A
Cap/Depr(3y)133.67%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-20.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8%
EPS Next Y-22.45%
EPS Next 2Y-26.68%
EPS Next 3Y-23.74%
EPS Next 5Y-14.28%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-51.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-58.47%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-66.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-63.7%
OCF growth 3YN/A
OCF growth 5YN/A